Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and
commercializes medicines in the areas of unmet medical need in the United
States, Europe, and internationally. The company provides Biktarvy, Genvoya,
Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products
for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for
the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi,
Vemlidy, and Viread for the treatment of liver diseases. It also offers
Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of
hematology, oncology, and cell therapy patients. In addition, the company
provides Letairis, an oral formulation for the treatment of pulmonary arterial
hypertension; Ranexa, an oral formulation for the treatment of chronic angina;
and AmBisome, a liposomal formulation for the treatment of serious invasive
fungal infections. Gilead Sciences, Inc. has collaboration agreements with
Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics,
Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV;
Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.;
Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co,
Inc. The company was incorporated in 1987 and is headquartered in Foster City,
California.
